title: Mid-term angiographic benefit of sirolimus-eluting stents compared with paclitaxel-eluting stents in patients with acute myocardial infarction.
abstract: BACKGROUND
  We compared angiographic and clinical outcomes among different drug-eluting stents (DESs) in Korean acute myocardial infarction (AMI) patients.
  
  
  METHODS
  A total of 109 consecutive AMI patients who underwent percutaneous coronary intervention (PCI) with either sirolimus-eluting (SES, n=56 pts) or paclitaxel-eluting stents (PES, n=53 pts) were enrolled from August 2004 to December 2006. The angiographic outcomes at 6 months and clinical outcomes at 1 year were compared between the two groups.
  
  
  RESULTS
  Baseline clinical and procedural characteristics were similar between the two groups. At 6 months, the rate of binary restenosis was 17.0% in the PES group compared with 3.6% in the SES group (p=0.026). Percent restenosis was 24.9+/-28.6% in the PES group compared with 11.2+/-17.6% in the SES group (p=0.004). Length of restenosis segment was 3.21+/-9.02 mm in the PES group compared with 0.89+/-2.38 mm in the SES group (p=0.048). Late loss was 0.73+/-0.89 mm in the PES group compared with 0.28+/-0.37 mm in the SES group (p=0.001). However, there were no differences in clinical outcomes at 1 year including mortality, myocardial infarction, repeat PCI, and major cardiac adverse events between two groups.
  
  
  CONCLUSIONS
  SES implantation in patients with AMI was associated with reduction in angiographic restenosis at 6 months compared with PES, however, these angiographic benefits were not translated into better clinical outcomes in real world clinical practice.
authors.affiliation: Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
authors.forename: Cheol Ung
authors.initials: CU
authors.lastname: Choi
authors.forename: Seung-Woon
authors.initials: SW
authors.lastname: Rha
authors.forename: Kang-Yin
authors.initials: KY
authors.lastname: Chen
authors.forename: Zhe
authors.initials: Z
authors.lastname: Jin
authors.forename: Yoshiyasu
authors.initials: Y
authors.lastname: Minami
authors.forename: Seung Yong
authors.initials: SY
authors.lastname: Shin
authors.forename: Jin Oh
authors.initials: JO
authors.lastname: Na
authors.forename: Soon Yong
authors.initials: SY
authors.lastname: Suh
authors.forename: Hong Euy
authors.initials: HE
authors.lastname: Lim
authors.forename: Jin Won
authors.initials: JW
authors.lastname: Kim
authors.forename: Eung Ju
authors.initials: EJ
authors.lastname: Kim
authors.forename: Chang Gyu
authors.initials: CG
authors.lastname: Park
authors.forename: Hong Seog
authors.initials: HS
authors.lastname: Seo
authors.forename: Dong Joo
authors.initials: DJ
authors.lastname: Oh
mesh_terms: D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000517:prevention & control; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D012044:Regression Analysis; D020123:Sirolimus / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D020123:Sirolimus